These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20149218)

  • 1. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
    Tung N; Wang Y; Collins LC; Kaplan J; Li H; Gelman R; Comander AH; Gallagher B; Fetten K; Krag K; Stoeckert KA; Legare RD; Sgroi D; Ryan PD; Garber JE; Schnitt SJ
    Breast Cancer Res; 2010; 12(1):R12. PubMed ID: 20149218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic features and immunophenotype of estrogen receptor-positive breast cancers in BRCA1 mutation carriers.
    Kaplan JS; Schnitt SJ; Collins LC; Wang Y; Garber JE; Montgomery K; West RB; Krag K; Fetten K; Lincoln A; Tung NM
    Am J Surg Pathol; 2012 Oct; 36(10):1483-8. PubMed ID: 22613997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.
    Tung N; Miron A; Schnitt SJ; Gautam S; Fetten K; Kaplan J; Yassin Y; Buraimoh A; Kim JY; Szász AM; Tian R; Wang ZC; Collins LC; Brock J; Krag K; Legare RD; Sgroi D; Ryan PD; Silver DP; Garber JE; Richardson AL
    Breast Cancer Res; 2010; 12(6):R95. PubMed ID: 21080930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
    Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
    Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
    Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA
    Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Davey MG; Richard V; Lowery AJ; Kerin MJ
    Eur J Cancer; 2021 Sep; 154():209-216. PubMed ID: 34284256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
    Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
    Mulligan AM; Couch FJ; Barrowdale D; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Robson M; Sherman M; Spurdle AB; Wappenschmidt B; Lee A; McGuffog L; Healey S; Sinilnikova OM; Janavicius R; Hansen Tv; Nielsen FC; Ejlertsen B; Osorio A; Muñoz-Repeto I; Durán M; Godino J; Pertesi M; Benítez J; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Bonanni B; Viel A; Pasini B; Papi L; Ottini L; Savarese A; Bernard L; Radice P; Hamann U; Verheus M; Meijers-Heijboer HE; Wijnen J; Gómez García EB; Nelen MR; Kets CM; Seynaeve C; Tilanus-Linthorst MM; van der Luijt RB; van Os T; Rookus M; Frost D; Jones JL; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Cook J; Donaldson A; Dorkins H; Gregory H; Eason J; Houghton C; Barwell J; Side LE; McCann E; Murray A; Peock S; Godwin AK; Schmutzler RK; Rhiem K; Engel C; Meindl A; Ruehl I; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Kast K; Preisler-Adams S; Varon-Mateeva R; Schoenbuchner I; Fiebig B; Heinritz W; Schäfer D; Gevensleben H; Caux-Moncoutier V; Fassy-Colcombet M; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Hardouin A; Berthet P; Muller D; Fricker JP; Mortemousque I; Pujol P; Coupier I; Lebrun M; Kientz C; Longy M; Sevenet N; Stoppa-Lyonnet D; Isaacs C; Caldes T; de la Hoya M; Heikkinen T; Aittomäki K; Blanco I; Lazaro C; Barkardottir RB; Soucy P; Dumont M; Simard J; Montagna M; Tognazzo S; D'Andrea E; Fox S; Yan M; Rebbeck T; Olopade O; Weitzel JN; Lynch HT; Ganz PA; Tomlinson GE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet M; Bhatia J; Kauff N; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Mai PL; Greene MH; Imyanitov E; O'Malley FP; Ozcelik H; Glendon G; Toland AE; Gerdes AM; Thomassen M; Kruse TA; Jensen UB; Skytte AB; Caligo MA; Soller M; Henriksson K; Wachenfeldt vA; Arver B; Stenmark-Askmalm M; Karlsson P; Ding YC; Neuhausen SL; Beattie M; Pharoah PD; Moysich KB; Nathanson KL; Karlan BY; Gross J; John EM; Daly MB; Buys SM; Southey MC; Hopper JL; Terry MB; Chung W; Miron AF; Goldgar D; Chenevix-Trench G; Easton DF; Andrulis IL; Antoniou AC; ; ; ; ; ; ; ;
    Breast Cancer Res; 2011; 13(6):R110. PubMed ID: 22053997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    Spurdle AB; Couch FJ; Parsons MT; McGuffog L; Barrowdale D; Bolla MK; Wang Q; Healey S; Schmutzler R; Wappenschmidt B; Rhiem K; Hahnen E; Engel C; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Ellis S; Frost D; Platte R; Perkins J; Evans DG; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Scuvera G; Manoukian S; Bonanni B; Mariette F; Fortuzzi S; Viel A; Pasini B; Papi L; Varesco L; Balleine R; Nathanson KL; Domchek SM; Offitt K; Jakubowska A; Lindor N; Thomassen M; Jensen UB; Rantala J; Borg Å; Andrulis IL; Miron A; Hansen TV; Caldes T; Neuhausen SL; Toland AE; Nevanlinna H; Montagna M; Garber J; Godwin AK; Osorio A; Factor RE; Terry MB; Rebbeck TR; Karlan BY; Southey M; Rashid MU; Tung N; Pharoah PD; Blows FM; Dunning AM; Provenzano E; Hall P; Czene K; Schmidt MK; Broeks A; Cornelissen S; Verhoef S; Fasching PA; Beckmann MW; Ekici AB; Slamon DJ; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Chang-Claude J; Flesch-Janys D; Rudolph A; Seibold P; Aittomäki K; Muranen TA; Heikkilä P; Blomqvist C; Figueroa J; Chanock SJ; Brinton L; Lissowska J; Olson JE; Pankratz VS; John EM; Whittemore AS; West DW; Hamann U; Torres D; Ulmer HU; Rüdiger T; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Eccles DM; Tapper WJ; Durcan L; Jones L; Peto J; dos-Santos-Silva I; Fletcher O; Johnson N; Dwek M; Swann R; Bane AL; Glendon G; Mulligan AM; Giles GG; Milne RL; Baglietto L; McLean C; Carpenter J; Clarke C; Scott R; Brauch H; Brüning T; Ko YD; Cox A; Cross SS; Reed MW; Lubinski J; Jaworska-Bieniek K; Durda K; Gronwald J; Dörk T; Bogdanova N; Park-Simon TW; Hillemanns P; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Burwinkel B; Marme F; Surovy H; Yang R; Anton-Culver H; Ziogas A; Hooning MJ; Collée JM; Martens JW; Tilanus-Linthorst MM; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Lindblom A; Margolin S; Joseph V; Robson M; Rau-Murthy R; González-Neira A; Arias JI; Zamora P; Benítez J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Peterlongo P; Zaffaroni D; Barile M; Capra F; Radice P; Teo SH; Easton DF; Antoniou AC; Chenevix-Trench G; Goldgar DE; ; ; ; ;
    Breast Cancer Res; 2014 Dec; 16(6):3419. PubMed ID: 25857409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathologic differences between BRCA1-, BRCA2-, and non-BRCA-associated breast cancers in a multiracial developing country.
    Yip CH; Taib NA; Choo WY; Rampal S; Thong MK; Teo SH
    World J Surg; 2009 Oct; 33(10):2077-81. PubMed ID: 19649760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
    Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
    Tilanus-Linthorst M; Verhoog L; Obdeijn IM; Bartels K; Menke-Pluymers M; Eggermont A; Klijn J; Meijers-Heijboer H; van der Kwast T; Brekelmans C
    Int J Cancer; 2002 Nov; 102(1):91-5. PubMed ID: 12353239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
    Foulkes WD; Stefansson IM; Chappuis PO; Bégin LR; Goffin JR; Wong N; Trudel M; Akslen LA
    J Natl Cancer Inst; 2003 Oct; 95(19):1482-5. PubMed ID: 14519755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of bilateral breast cancers in BRCA carriers.
    Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
    Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
    J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
    Musolino A; Michiara M; Bella MA; Naldi N; Zanelli P; Bortesi B; Capelletti M; Soldani L; Camisa R; Martella E; Franciosi V; Savi M; Neri TM; Ardizzoni A; Cascinu S
    Tumori; 2005; 91(6):505-12. PubMed ID: 16457150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.